Literature DB >> 33513209

OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies.

Liana Fraenkel1,2, Zhenglin Wei3, Christine Ramsey4,5, Carole Wiedmeyer6, Kaleb Michaud7,8, Tuhina Neogi9, W Benjamin Nowell6, Shilpa Venkatachalam6, David A Broniatowski3.   

Abstract

OBJECTIVES: A measure that encompasses both benefits and harms at the individual patient level may facilitate comparisons between treatment options and improve shared decision-making. The objective of this study was to develop a patient reported measure to capture overall experience (including both benefits and harms) of treatment using rheumatoid arthritis (RA) as a case example.
METHODS: Hierarchies for treatment benefits are known. Therefore, we developed a hierarchy of adverse events (AEs) using a series of trajectory mapping and paired comparison surveys. We subsequently used these data to construct a paired comparison survey, asking patients to compare options including both a specified level of benefit and an AE. These data were used to generate a hierarchy of overall experience on treatment.
RESULTS: 782 participants completed a series of three surveys. The trajectory mapping procedure and a paired comparison survey led to the generation of a hierarchy of AEs with nine levels ranging from No AEs to irreversible serious complications. In a third survey, in which AEs were paired with benefits, participants' ratings generated a 6-level hierarchy of overall experiences ranging from Major improvement + No, mild or manageable AEs (Level 1) to No improvement + Irreversible AEs (Level 6).
CONCLUSIONS: Using a trajectory mapping approach, we developed a patient reported measure representing the distribution of patients' overall experiences on treatment. The intent of this measure is to enable patients and their physicians to compare the percentage of patients experiencing each level of outcome, from most to least desirable, across treatments.

Entities:  

Year:  2021        PMID: 33513209      PMCID: PMC7846019          DOI: 10.1371/journal.pone.0245598

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  9 in total

1.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

2.  Trajectory mapping: a new nonmetric scaling technique.

Authors:  W Richards; J J Koenderink
Journal:  Perception       Date:  1995       Impact factor: 1.490

3.  Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study.

Authors:  Edward Keystone; Mark C Genovese; Lars Klareskog; Elizabeth C Hsia; Stephen Hall; Pedro C Miranda; Jacek Pazdur; Sang-Cheol Bae; William Palmer; Stephen Xu; Mahboob U Rahman
Journal:  Ann Rheum Dis       Date:  2010-05-05       Impact factor: 19.103

4.  What Do "None," "Mild," "Moderate," "Severe," and "Very Severe" Mean to Patients With Cancer? Content Validity of PRO-CTCAE™ Response Scales.

Authors:  Thomas M Atkinson; Jennifer L Hay; Amylou C Dueck; Sandra A Mitchell; Tito R Mendoza; Lauren J Rogak; Lori M Minasian; Ethan Basch
Journal:  J Pain Symptom Manage       Date:  2017-11-10       Impact factor: 3.612

5.  Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).

Authors:  Scott R Evans; Daniel Rubin; Dean Follmann; Gene Pennello; W Charles Huskins; John H Powers; David Schoenfeld; Christy Chuang-Stein; Sara E Cosgrove; Vance G Fowler; Ebbing Lautenbach; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2015-06-25       Impact factor: 9.079

6.  A theory of medical decision making and health: fuzzy trace theory.

Authors:  Valerie F Reyna
Journal:  Med Decis Making       Date:  2008-11-17       Impact factor: 2.583

7.  Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.

Authors:  A Goldhirsch; R D Gelber; R J Simes; P Glasziou; A S Coates
Journal:  J Clin Oncol       Date:  1989-01       Impact factor: 44.544

8.  The net clinical benefit of warfarin anticoagulation in atrial fibrillation.

Authors:  Daniel E Singer; Yuchiao Chang; Margaret C Fang; Leila H Borowsky; Niela K Pomernacki; Natalia Udaltsova; Alan S Go
Journal:  Ann Intern Med       Date:  2009-09-01       Impact factor: 25.391

9.  The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

Authors:  D T Felson; J J Anderson; M Boers; C Bombardier; M Chernoff; B Fried; D Furst; C Goldsmith; S Kieszak; R Lightfoot
Journal:  Arthritis Rheum       Date:  1993-06
  9 in total
  4 in total

1.  Supporting Health and Medical Decision Making: Findings and Insights from Fuzzy-Trace Theory.

Authors:  Valerie F Reyna; Sarah Edelson; Bridget Hayes; David Garavito
Journal:  Med Decis Making       Date:  2022-06-23       Impact factor: 2.749

Review 2.  The Application of Preference Elicitation Methods in Clinical Trial Design to Quantify Trade-Offs: A Scoping Review.

Authors:  Megan Thomas; Deborah A Marshall; Daksh Choudhary; Susan J Bartlett; Adalberto Loyola Sanchez; Glen S Hazlewood
Journal:  Patient       Date:  2021-12-20       Impact factor: 3.481

3.  Correction: OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies.

Authors: 
Journal:  PLoS One       Date:  2021-03-09       Impact factor: 3.240

4.  Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions.

Authors:  W Benjamin Nowell; Peter A Merkel; Robert N McBurney; Kalen Young; Shilpa Venkatachalam; Dianne G Shaw; Angela Dobes; Emily Cerciello; Laura Kolaczkowski; Jeffrey R Curtis; Michael D Kappelman
Journal:  Patient       Date:  2021-04-27       Impact factor: 3.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.